(Q37129663)

English

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

scientific article published on 26 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Claudine Isaacs

1

object named as

Claudine Isaacs

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3

object named as

Minetta C Liu

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Pia Herbolsheimer

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Mary Wilkinson

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yvonne Ottaviano

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Gina G Chung

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Robert Warren

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jennifer Eng-Wong

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Philip Cohen

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Karen L Smith

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Karen Creswell

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Antonella Novielli

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rebecca Slack

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

26 October 2010

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

125

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

137-143

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

https://scigraph.springernature.com/pub.10.1007/s10549-010-1226-z

0 references

New strategies in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Synergistic activity of letrozole and sorafenib on breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

14 September 2017

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

27 June 2018

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

3 September 2018

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

3 September 2018

Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

3 September 2018

Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

3 September 2018

Ras activation in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756315

3 September 2018

Hazard rates of recurrence following diagnosis of primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20976541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raf-1 protein expression in human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20976541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-010-1226-Z

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37129663&oldid=2094589466"